Phase III Blincyto TOWER Study Stopped Early

The Phase III TOWER study of Amgen's bispecific CD19-directed CD3 T cell engager (BiTE) Blincyto (blinatumomab) has been halted early after a pre-specified analysis showed that it has already met the primary overall survival endpoint in Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).